Compare Amphastar Pharmaceuticals Inc (AMPH) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Johnson Controls International PLC — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Johnson Controls International PLC trades at $155.47 (market cap $91.29B). The key difference: Johnson Controls International PLC is far larger — about 105.7× Amphastar Pharmaceuticals Inc's market cap, and Johnson Controls International PLC pays a 1.06% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | JCI | |
|---|---|---|
Market Cap | $863.95M | $91.29B |
Sector | Health | Industrials |
52-Week High | $30.81 | $154.76 |
52-Week Low | $16.87 | $103.52 |
Enterprise Value | $1.26B | $100.12B |
Dividend Yield | — | 1.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Johnson Controls International (JCI) trades at $152.21, down 1.51% on the day, but maintains a bullish technical outlook with strong analyst support. The company reported robust Q2 2026 earnings, beating estimates with EPS of $1.42 versus $1.30 expected, and raised full-year guidance. Fundamentals show solid revenue growth and expanding net income margins, though valuation multiples like a P/E of 42.88 appear elevated. Recent news highlights strong demand for its thermal management systems, particularly in data centers.
JCI's outlook is positive, driven by operational strength and strategic positioning in high-growth markets like AI infrastructure. Investment opportunities include continued earnings beats and market share gains in energy efficiency solutions. Key risks involve high valuation sensitivity, competitive pressures, and macroeconomic factors affecting construction and industrial spending. The consensus price target of $168.25 suggests ~10% upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
